Eur Rev Med Pharmacol Sci 2022; 26 (16): 5939-5945

DOI: 10.26355/eurrev_202208_29534

Study on the effects of ranibizumab as a pretreatment for vitrectomy in proliferative diabetic retinopathy: a retrospective cohort study

H.-W. Zhou, K. Chen

Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, China. ve0307@163.com


OBJECTIVE: The effects of intravitreal ranibizumab (IVR) as a pretreatment for vitrectomy in proliferative diabetic retinopathy (PDR) need further study. The aim of this study is to further analyze this topic.

PATIENTS AND METHODS: The study group (n=26) was treated with IVR, while the control group (n=28) was not. The best corrected visual acuity (BCVA) at different time points within each group was compared. Operation time, intraoperative bleeding, silicone oil usage, iatrogenic retinal rupture and complications were compared between the groups.

RESULTS: BCVA at the 1st month after vitrectomy was significantly improved in the study group (t=2.081, p=0.047) but not in the control group (I=0.164, p=0.871). At the 1st month after vitrectomy, the BCVA of the study group was significantly higher than that of the control group (t=2.1467, p=0.0365). At the 6th month after vitrectomy, the BCVA of the study group was significantly higher than that of the control group (t=2.0424, p=0.0462). The operation time in the study group was significantly shorter than that in the control group (W=2.212, p<0.05). The rates of mild and severe intraoperative bleeding in the study group were significantly lower than those in the control group (p<0.05, respectively). There was no significant difference in complications between the two groups (p>0.05).

CONCLUSIONS: IVR before vitrectomy in patients with PDR can significantly improve BCVA in the early stage, improve BCVA at the 6th month after the operation, reduce the operation time and reduce intraoperative bleeding.

Free PDF Download

To cite this article

H.-W. Zhou, K. Chen
Study on the effects of ranibizumab as a pretreatment for vitrectomy in proliferative diabetic retinopathy: a retrospective cohort study

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 16
Pages: 5939-5945
DOI: 10.26355/eurrev_202208_29534